There has been increasing regulatory scrutiny for both Ad Boards and Speaker Programs as a result of legislation such as the Sunshine Act. Pharma companies must report the number of ad board meetings that are held every year and the amount that a company spends on such meetings. Pharma is also required to report what each speaker is paid. As a result of this, it is becoming increasingly difficult for pharma companies to convince quality speakers that the time and money lost being away from their practice is worthwhile, thus, becoming ever more difficult to convince attendees of the same.
